Genetic determinants of dabigatran safety (CES1 gene rs2244613 polymorphism) in the Russian population: multi-ethnic analysis
- 22 Downloads
This study was aimed to investigate the prevalence of the CES1 gene (c.1168-33A > C, rs2244613) polymorphism among 12 different ethnic groups living in Russia to provide a basis for future clinical studies concerning genetic determinants of dabigatran safety. The study involved 1630 apparently healthy, unrelated, and chronic medication-free volunteers of both genders from 12 different ethnic groups in Russia: 136 Russians, 90 Avars, 50 Dargins, 46 Laks, 120 Kabardians, 112 Balkars, 244 Ossetians, 206 Mari, 204 Mordvinians, 238 Chuvashes, 114 Buryats and 70 Nanays. Genotyping was performed by using real-time polymerase chain reaction-based methods. The allelic prevalence of the ethnic groups was compared with Caucasus population participating in the RE-LY study. Statistically significant differences for the following gene polymorphism were found between all ethnic groups and RE-LY participants. Based on obtained results, it can be assumed that patients of all ethnic groups living in Russia taking dabigatran have a lower risk of bleeding.
KeywordsCES1 Rs2244613 Dabigatran Ethnicity Pharmacogenetics
The funding organization played no role in the study design, in the collection, analysis, and interpretation of data as well as in the writing of the article and in the decision to submit the article for publication.
Compliance with ethical standards
Conflict of interest
The work was carried out with the financial support of OOO Boehringer Ingelheim (Moscow, Russian Federation). All the authors report no conflicts of interest in this work.
- 1.Alwan A (2011) Global status report on noncommunicable diseases 2010 Introduction. In: A. Alwan, editor. Global status report on noncommunicable diseases 2010. World Health Organization, Geneva. pp VII–IX. https://www.who.int/nmh/publications/ncd_report2010/en/. Accessed 26 Aug 2018
- 2.World Health Organization website. http://www.who.int/cardiovascular_diseases/ru. Accessed 26 Aug 2018
- 4.Napalkov DA, Sokolova AA, Rodionov AV (2016) Atrial fibrillation and ischemic heart disease: how to combine antiplatelet and anticoagulant therapy, depending on the clinical situation? Ration Pharmacother Cardiol 2(21):191–195. https://doi.org/10.20996/1819-6446-2016-12-2-191-195 (In Russ)CrossRefGoogle Scholar
- 7.Sychev DA, Kazakov RE, Otdelenov VA, Prokofiev AB (2013) Applications of pharmacogenetic testing for personalization of therapy with oral anticoagulants in Russia. Ration Pharmacother Cardiol 9(5):525–531. https://doi.org/10.20996/1819-6446-2013-9-5-525-531 CrossRefGoogle Scholar
- 10.Mazur-Bialy AI, Zdebska K, Wypasek E, Undas A (2013) Repeated bleeding complications during therapy with vitamin K antagonists in a patient with the VKORC1*2A and the CYP2C9*3/*3 alleles: genetic testing to support switching to new oral anticoagulants. Thromb Res 131(3):279–280. https://doi.org/10.1016/j.thromres.2012.12.008 CrossRefGoogle Scholar
- 25.PharmGKB website: https://www.pharmgkb.org/variant/PA166155037/overview. Accessed 1 Sept 2018
- 29.Balanovsky OP (2017) Gene pool of Europe. The Partnership of Scientific Publications, Moscow (In Russ.)Google Scholar
- 31.Golukhova EZ, Grigoryan MV, Ryabinina MN (2014) Modern aspects of clopidogrel pharmacogenetics and its clinical relevance. Creat Cardiol 3:39–52. (In Russ.)Google Scholar
- 35.Romodanovsky DP, Khapaev BA, Ignatiev IV et al (2010) Frequencies the «slow» allele variants of the genes coding isoenzymes of cytochrome Р450 CYP2D6, CYP2C19, CYP2C9 in Karachaevs and Circassians. Biomedicine 2:33–37 (In Russ.)Google Scholar
- 37.NCBI website: https://www.ncbi.nlm.nih.gov/snp/?term=CES1. Accessed 14 Sept 2018
- 40.Sychev DA, Levanov AN, Shelekhova TV et al (2018) The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty. Pharmgenomics Pers Med 11:127–137. https://doi.org/10.2147/PGPM.S169277 Google Scholar
- 41.Reilly PA, Lehr T, Haertter S et al (2014) The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long Term Anticoagulation Therapy). J Am Coll Cardiol 63:321–328. https://doi.org/10.1016/j.jacc.2013.07.104 CrossRefGoogle Scholar
- 42.Eriksson BI, Dahl OE, Buller HR et al (2005) A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 3:103–111. https://doi.org/10.1111/j.1538-7836.2004.01100.x CrossRefGoogle Scholar